ArticleJTO clinical and research reports2025

Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study.

Azam Ghafoor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.